Investors

FGEN (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$20.42
Change (%) Stock is Down 1.63 (7.39%)
Volume467,317
Data as of 09/29/16 4:00 p.m. ET
Refresh quote
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs.
Recent Press ReleasesMore »
DateTitle 
08/08/16FibroGen Reports Financial Results for the Second Quarter of 2016Printer Friendly Version
08/02/16FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016Printer Friendly Version
07/25/16Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in JapanPrinter Friendly Version
07/08/16FibroGen Announces Receipt of $62 Million License Payment from AstraZenecaPrinter Friendly Version
Upcoming EventsMore »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources